Published in Women's Health Weekly, September 15th, 2005
S.Y. Moon and associates at Seoul National University conducted a study "To assess the clinical efficacy and safety of the gonadotropin-releasing hormone (GnRH) antagonist, ganirelix (Orgalutran), treatment in women undergoing COH for in vitro fertilization and embryo transfer (IVF-ET) in Korean women."
The scientists explained, "This was a non-comparative, open-label, single-center trial carried out on 31 infertile Korean women. A daily dose of 0.25 mg of the GnRH antagonist, ganirelix, was given,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly